nach oben

Erschienen in:

23.07.2015 | Original Article

Serine-arginine protein kinase 1 is associated with hepatocellular carcinoma progression and poor patient survival

verfasst von: Jing Zhang, Hua Jiang, Wenfei Xia, Yizhou Jiang, Xiaoyun Tan, Peiying Liu, Hongyun Jia, Xuewei Yang, Gang Shen

Erschienen in: Tumor Biology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The pre-mRNA splicing regulator serine-arginine protein kinase 1 (SRPK1) promotes cancer development and various pathophysiological processes. However, the clinical relevance of SRPK1 in hepatocellular carcinoma (HCC) is not clear. This study investigates the expression and prognostic value of SRPK1 in HCC. We found that SRPK1 expression was significantly upregulated at the mRNA and protein level in all HCC cell lines or HCC tissue samples compared with the hepatic cell line or matched noncancerous tissue samples, respectively. Higher SRPK1 expression significantly correlated with clinical staging (p = 0.031), survival time (p = 0.004), and gender (p = 0.011) of HCC patients. Together, our study showed that SRPK1 is overexpressed in HCC and may be a promising indicator of prognosis for HCC patients.

Scott T. Eblen: Regulation of chemoresistance via alternative messenger RNA splicing. Biochem Pharmacol. 2012;8:1063–72. doi:10.1016/j.bcp.2011.12.041.

Graveley BR. Sorting out the complexity of SR protein functions. RNA. 2000;9:1197–211.CrossRef

Papoutsopoulou S, Nikolakaki E, Chalepakis G, Kruft V, Chevaillier P, Giannakouros T. SR protein-specific kinase 1 is highly expressed in testis and phosphorylates protamine 1. Nucleic Acids Res. 1999;27:2972–80.CrossRefPubMedPubMedCentral

Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res. 2007;5:2072–80.CrossRef

Wu Q, Chang Y, Zhang L, Zhang Y, Tian T, Feng G, et al. SRPK1 dissimilarly impacts on the growth, metastasis, chemosensitivity and angiogenesis of glioma in normoxic and hypoxic conditions. J Cancer. 2013;9:727–35. doi:10.7150/jca.7576. eCollection 2013.CrossRef

Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, Quinn DI, Abad A, Neamati N. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol. 2006;1:225–35.

Odunsi K, Mhawech-Fauceglia P, Andrews C, Beck A, Amuwo O, Lele S, et al. Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in cisplatin cytotoxicity in vitro. PLoS One. 2012;7(12):e51030. doi:10.1371/journal.pone.0051030.CrossRefPubMedPubMedCentral

Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem. 2010;285(8):5532–40. doi:10.1074/jbc.M109.074930.CrossRefPubMed

Gammons MVR, Dick AD, Harper SJ, Bates DO. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2013;54:5797–806. doi:10.1167/iovs.13-11634.CrossRefPubMed

10.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 2002;2005(55):74–108.

11.

Luca Faloppi B, Mario Scartozzi A, Elena Maccaroni B, Marzia Di Pietro Paolo C, Rossana Berardi A, Michela Del Prete A, Stefano C. Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-taylored therapeutic options. Cancer Treat Rev 2011;(37):169–177.

12.

Franceschi S, Raza SA. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett. 2009;286:5–8.CrossRefPubMed

13.

Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med. 2008;29(1-2):130–43.CrossRefPubMed

14.

Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma An audit of 343 patients. Ann Surg. 1995;221:291–8.CrossRefPubMedPubMedCentral

15.

Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237:536–43.PubMedPubMedCentral

16.

Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, Nakamura S, et al. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol. 2012;47(4):421–6. doi:10.1007/s00535-011-0492-9.CrossRefPubMed

17.

Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, et al. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011;9:166. doi:10.1186/1479-5876-9-166.CrossRefPubMedPubMedCentral

18.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods. 2001;25:402–8.CrossRefPubMed

19.

Baig S. Gender disparity in infections of Hepatitis B virus. S J Coll Physicians Surg Pak. 2009;19(9):598–600.

20.

Pawlik TM, Delman KA, Vauthey J-N, Nagorney DM, Ng IO, Ikai I, et al. Tumor Size Predicts Vascular Invasion and Histologic Grade: Implications for Selection of Surgical Treatment for Hepatocellular Carcinoma. Liver Transpl. 2005;9:1086–92.CrossRef

21.

Hayes GM, Carrigan PE, Beck AM, Miller LJ. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res. 2006;7:3819–27.CrossRef

22.

Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, et al. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochem Soc Trans. 2012;40(4):831–5. doi:10.1042/BST20120051.CrossRefPubMed

23.

Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 2011;20(6):768–80. doi:10.1016/j.ccr.2011.10.016.CrossRefPubMedPubMedCentral

24.

Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;14:4123–31.

25.

Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO. The anti-angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans. 2009;37:1207–13. doi:10.1042/BST0371207.CrossRefPubMedPubMedCentral

26.

Fukuhara T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y, et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci U S A. 2006;30:11329–33.CrossRef

27.

Karakama Y, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Nishimura-Sakurai Y, et al. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob Agents Chemother. 2010;8:3179–86. doi:10.1128/AAC.00113-10.CrossRef

Titel: Serine-arginine protein kinase 1 is associated with hepatocellular carcinoma progression and poor patient survival
verfasst von: Jing Zhang
Hua Jiang
Wenfei Xia
Yizhou Jiang
Xiaoyun Tan
Peiying Liu
Hongyun Jia
Xuewei Yang
Gang Shen
Publikationsdatum: 23.07.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 1/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3771-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Serine-arginine protein kinase 1 is associated with hepatocellular carcinoma progression and poor patient survival

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Estrogen potentiates reactive oxygen species (ROS) tolerance to initiate carcinogenesis and promote cancer malignant transformation

Immature myeloid cells and tolerogenic cytokine profile in lung adenocarcinoma metastatic lymph nodes assessed by endobronchial ultrasound

Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: its correlation with tumor grade and stage

CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma

The role of stearoyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie